Molimard M - Search Results

1

Drug interactions between inhaled corticosteroids and enzymatic inhibitors.

Daveluy A, Raignoux C, Miremont-Salamé G, Girodet PO, Moore N, Haramburu F, Molimard M. Daveluy A, et al. Among authors: molimard m. Eur J Clin Pharmacol. 2009 Jul;65(7):743-5. doi: 10.1007/s00228-009-0653-4. Epub 2009 Apr 28. Eur J Clin Pharmacol. 2009. PMID: 19399485 Free article. No abstract available.

2

Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation.

Molimard M, Girodet PO, Pollet C, Fourrier-Réglat A, Daveluy A, Haramburu F, Fayon M, Tabarin A. Molimard M, et al. Drug Saf. 2008;31(9):769-74. doi: 10.2165/00002018-200831090-00005. Drug Saf. 2008. PMID: 18707191

3

Agreement of expert judgment in causality assessment of adverse drug reactions.

Arimone Y, Bégaud B, Miremont-Salamé G, Fourrier-Réglat A, Moore N, Molimard M, Haramburu F. Arimone Y, et al. Among authors: molimard m. Eur J Clin Pharmacol. 2005 May;61(3):169-73. doi: 10.1007/s00228-004-0869-2. Epub 2005 Apr 13. Eur J Clin Pharmacol. 2005. PMID: 15827761

4

Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions.

Arimone Y, Miremont-Salamé G, Haramburu F, Molimard M, Moore N, Fourrier-Réglat A, Bégaud B. Arimone Y, et al. Among authors: molimard m. Br J Clin Pharmacol. 2007 Oct;64(4):482-8. doi: 10.1111/j.1365-2125.2007.02937.x. Epub 2007 Aug 15. Br J Clin Pharmacol. 2007. PMID: 17711539 Free PMC article.

5

Inhaled triple therapy in chronic obstructive pulmonary disease.

Molimard M, Girodet PO, Moore N. Molimard M, et al. Lancet. 2018 Sep 29;392(10153):1112. doi: 10.1016/S0140-6736(18)31798-7. Lancet. 2018. PMID: 30303074 No abstract available.

6

Interest of pharmacoepidemiology for the study of inhaled drugs.

Molimard M, Girodet PO, Van Ganse E. Molimard M, et al. Therapie. 2019 Apr;74(2):233-237. doi: 10.1016/j.therap.2018.08.002. Epub 2018 Oct 19. Therapie. 2019. PMID: 30392699

7

Paradoxal effect of salbutamol in an in vitro model of bronchoprotection.

Girodet PO, Berger P, Martinez B, Marthan R, Advenier C, Molimard M. Girodet PO, et al. Among authors: molimard m. Fundam Clin Pharmacol. 2005 Apr;19(2):179-86. doi: 10.1111/j.1472-8206.2005.00320.x. Fundam Clin Pharmacol. 2005. PMID: 15810898

8

A new method for assessing drug causation provided agreement with experts' judgment.

Arimone Y, Bégaud B, Miremont-Salamé G, Fourrier-Réglat A, Molimard M, Moore N, Haramburu F. Arimone Y, et al. Among authors: molimard m. J Clin Epidemiol. 2006 Mar;59(3):308-14. doi: 10.1016/j.jclinepi.2005.08.012. J Clin Epidemiol. 2006. PMID: 16488362

9

Effectiveness of Fluticasone Furoate-Vilanterol in COPD.

Girodet PO, Raherison Ch, Molimard M. Girodet PO, et al. Among authors: molimard m. N Engl J Med. 2016 Dec 29;375(26):2605-6. doi: 10.1056/NEJMc1613713. N Engl J Med. 2016. PMID: 28032960 No abstract available.

10

Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients.

Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, Droz-Perroteau C, Lassalle R, Moore N, Girodet PO. Molimard M, et al. Eur Respir J. 2017 Feb 15;49(2):1601794. doi: 10.1183/13993003.01794-2016. Print 2017 Feb. Eur Respir J. 2017. PMID: 28182569 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

266 results

Search Page